RYTM - リズム・ファ―マシュ―ティカルズ (Rhythm Pharmaceuticals Inc.)

RYTMのニュース

   Hedge Funds Are Selling Rhythm Pharmaceuticals, Inc. (RYTM)  2020/06/26 15:20:19 Yahoo Finance
In this article you are going to find out whether hedge funds think Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge
   Rhythm Pharmaceuticals prices stock offering; shares down 11% after hours  2019/10/16 04:10:23 Seeking Alpha
Rhythm Pharmaceuticals (RYTM) prices its public offering of 8.11M common shares at $18.50/share. The greenshoe option is for another 1.22M common shares Cl
   Rhythm Rips Higher After Obesity Drug Aces Late-Stage Trials  2019/08/07 13:49:29 Benzinga
Shares of the thinly traded small-cap biotech Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) were rallying by more than 15% Wednesday. What Happened Boston-based Rhythm , which focuses on therapies for rare genetic disorders of obesity, announced positive topline results from two pivotal Phase 3 trials that evaluated its setmelanotide for the treatment of pro-opiomelanocortin, or POMC, and leptin receptor, or LEPR, deficiency obesities. Setmelanotide is Rhythm's melanocortin-4 receptor agonist. The company said both studies met their primary endpoints and all key secondary endpoints, showing a statistically significant and clinically meaningfully effect … Full story available on Benzinga.com
   The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster  2019/07/31 11:06:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Medpace Holdings Inc (NASDAQ: MEDP )(reported strong second-quarter results ) Novocure Ltd (NASDAQ: NVCR ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 30) Alimera Sciences Inc (NASDAQ: ALIM )(reacted to second-quarter results) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Equillium Inc (NASDAQ: EQ ) Medtronic PLC (NYSE: MDT ) Obseva SA (NASDAQ: OBSV ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Stocks In Focus Roche Extends Offer Period For Spark Buy Once Again Roche Holdings AG Basel ADR (OTC: RHHBY ) and Spark Therapeutics Inc (NASDAQ: ONCE ) announced Wednesday Roche has extended the offering period for its previously announced tender offer to buy all outstanding shares of Spark for $114.50 …
   The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana  2019/06/12 11:34:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Hemispherx BioPharma, Inc (NYSE: HEB )(started trading on a 1-for-44 reverse split adjusted basis) Down In The Dumps (Biotech stocks hitting 52-week lows on June 11) Acer Therapeutics Inc (NASDAQ: ACER ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CymaBay Therapeutics Inc (NASDAQ: CBAY )( reported negative mid-stage trial results for its investigational NASH candidate seladelpar) Endo International PLC (NASDAQ: ENDP ) GENFIT S A/ADR (NASDAQ: GNFT )(moved in sympathy with CymaBay) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Novavax, Inc. (NASDAQ: NVAX ) Puma Biotechnology Inc (NASDAQ: PBYI ) RA Medical Systems Inc (NYSE: RMED ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) TherapeuticsMD Inc (NASDAQ: TXMD ) Unum Therapeutics Inc (NASDAQ: UMRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Stock In Focus Nuvectra Files For Approval For Spinal Cord Stimulation System Medical device company Nuvectra Corp (NASDAQ: NVTR ) filed its regulatory submission with the FDA for it full-body MR-conditional approval for its Algovita spinal cord stimulation, or SCS, system.
   Hedge Funds Are Selling Rhythm Pharmaceuticals, Inc. (RYTM)  2020/06/26 15:20:19 Yahoo Finance
In this article you are going to find out whether hedge funds think Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge
   Rhythm Pharmaceuticals prices stock offering; shares down 11% after hours  2019/10/16 04:10:23 Seeking Alpha
Rhythm Pharmaceuticals (RYTM) prices its public offering of 8.11M common shares at $18.50/share. The greenshoe option is for another 1.22M common shares Cl
   Rhythm Rips Higher After Obesity Drug Aces Late-Stage Trials  2019/08/07 13:49:29 Benzinga
Shares of the thinly traded small-cap biotech Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) were rallying by more than 15% Wednesday. What Happened Boston-based Rhythm , which focuses on therapies for rare genetic disorders of obesity, announced positive topline results from two pivotal Phase 3 trials that evaluated its setmelanotide for the treatment of pro-opiomelanocortin, or POMC, and leptin receptor, or LEPR, deficiency obesities. Setmelanotide is Rhythm's melanocortin-4 receptor agonist. The company said both studies met their primary endpoints and all key secondary endpoints, showing a statistically significant and clinically meaningfully effect … Full story available on Benzinga.com
   The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster  2019/07/31 11:06:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Medpace Holdings Inc (NASDAQ: MEDP )(reported strong second-quarter results ) Novocure Ltd (NASDAQ: NVCR ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 30) Alimera Sciences Inc (NASDAQ: ALIM )(reacted to second-quarter results) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Equillium Inc (NASDAQ: EQ ) Medtronic PLC (NYSE: MDT ) Obseva SA (NASDAQ: OBSV ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Stocks In Focus Roche Extends Offer Period For Spark Buy Once Again Roche Holdings AG Basel ADR (OTC: RHHBY ) and Spark Therapeutics Inc (NASDAQ: ONCE ) announced Wednesday Roche has extended the offering period for its previously announced tender offer to buy all outstanding shares of Spark for $114.50 …
   The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana  2019/06/12 11:34:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Hemispherx BioPharma, Inc (NYSE: HEB )(started trading on a 1-for-44 reverse split adjusted basis) Down In The Dumps (Biotech stocks hitting 52-week lows on June 11) Acer Therapeutics Inc (NASDAQ: ACER ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CymaBay Therapeutics Inc (NASDAQ: CBAY )( reported negative mid-stage trial results for its investigational NASH candidate seladelpar) Endo International PLC (NASDAQ: ENDP ) GENFIT S A/ADR (NASDAQ: GNFT )(moved in sympathy with CymaBay) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Novavax, Inc. (NASDAQ: NVAX ) Puma Biotechnology Inc (NASDAQ: PBYI ) RA Medical Systems Inc (NYSE: RMED ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) TherapeuticsMD Inc (NASDAQ: TXMD ) Unum Therapeutics Inc (NASDAQ: UMRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Stock In Focus Nuvectra Files For Approval For Spinal Cord Stimulation System Medical device company Nuvectra Corp (NASDAQ: NVTR ) filed its regulatory submission with the FDA for it full-body MR-conditional approval for its Algovita spinal cord stimulation, or SCS, system.
   Hedge Funds Are Selling Rhythm Pharmaceuticals, Inc. (RYTM)  2020/06/26 15:20:19 Yahoo Finance
In this article you are going to find out whether hedge funds think Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge
   Rhythm Pharmaceuticals prices stock offering; shares down 11% after hours  2019/10/16 04:10:23 Seeking Alpha
Rhythm Pharmaceuticals (RYTM) prices its public offering of 8.11M common shares at $18.50/share. The greenshoe option is for another 1.22M common shares Cl
   Rhythm Rips Higher After Obesity Drug Aces Late-Stage Trials  2019/08/07 13:49:29 Benzinga
Shares of the thinly traded small-cap biotech Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) were rallying by more than 15% Wednesday. What Happened Boston-based Rhythm , which focuses on therapies for rare genetic disorders of obesity, announced positive topline results from two pivotal Phase 3 trials that evaluated its setmelanotide for the treatment of pro-opiomelanocortin, or POMC, and leptin receptor, or LEPR, deficiency obesities. Setmelanotide is Rhythm's melanocortin-4 receptor agonist. The company said both studies met their primary endpoints and all key secondary endpoints, showing a statistically significant and clinically meaningfully effect … Full story available on Benzinga.com
   The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster  2019/07/31 11:06:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Medpace Holdings Inc (NASDAQ: MEDP )(reported strong second-quarter results ) Novocure Ltd (NASDAQ: NVCR ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 30) Alimera Sciences Inc (NASDAQ: ALIM )(reacted to second-quarter results) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Equillium Inc (NASDAQ: EQ ) Medtronic PLC (NYSE: MDT ) Obseva SA (NASDAQ: OBSV ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Stocks In Focus Roche Extends Offer Period For Spark Buy Once Again Roche Holdings AG Basel ADR (OTC: RHHBY ) and Spark Therapeutics Inc (NASDAQ: ONCE ) announced Wednesday Roche has extended the offering period for its previously announced tender offer to buy all outstanding shares of Spark for $114.50 …
   The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana  2019/06/12 11:34:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Hemispherx BioPharma, Inc (NYSE: HEB )(started trading on a 1-for-44 reverse split adjusted basis) Down In The Dumps (Biotech stocks hitting 52-week lows on June 11) Acer Therapeutics Inc (NASDAQ: ACER ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CymaBay Therapeutics Inc (NASDAQ: CBAY )( reported negative mid-stage trial results for its investigational NASH candidate seladelpar) Endo International PLC (NASDAQ: ENDP ) GENFIT S A/ADR (NASDAQ: GNFT )(moved in sympathy with CymaBay) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Novavax, Inc. (NASDAQ: NVAX ) Puma Biotechnology Inc (NASDAQ: PBYI ) RA Medical Systems Inc (NYSE: RMED ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) TherapeuticsMD Inc (NASDAQ: TXMD ) Unum Therapeutics Inc (NASDAQ: UMRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Stock In Focus Nuvectra Files For Approval For Spinal Cord Stimulation System Medical device company Nuvectra Corp (NASDAQ: NVTR ) filed its regulatory submission with the FDA for it full-body MR-conditional approval for its Algovita spinal cord stimulation, or SCS, system.

calendar